OncoMatch

OncoMatch/Clinical Trials/NCT04703101

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Is NCT04703101 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Capecitabine and Fluorouracil for locally advanced rectal carcinoma.

Phase 1RecruitingJonsson Comprehensive Cancer CenterNCT04703101Data as of May 2026

Treatment: Capecitabine · Fluorouracil · Leucovorin · OxaliplatinThis phase I trial investigates how well short-course radiation therapy followed by combination chemotherapy works in treating patients with stage II-III rectal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as leucovorin, fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving short-course radiation therapy and combination chemotherapy may reduce the need for surgery and therefore improve quality of life.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage II, III

Performance status

KARNOFSKY OR ECOG 0–2

Karnofsky performance status (KPS) >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-2

Prior therapy

Cannot have received: radiation therapy

Lab requirements

Blood counts

ANC > 1.5 cell/mm^3; Hgb > 8.0 gm/dL; PLT > 150,000/mm^3

Liver function

Total bilirubin <= 1.5 x upper limit of normal; AST and ALT <= 3 x upper limit of normal

ANC > 1.5 cell/mm^3; Hgb > 8.0 gm/dL; PLT > 150,000/mm^3; Total bilirubin <= 1.5 x upper limit of normal; AST and ALT <= 3 x upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify